Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis-Reference-Cited by-同舟云学术

Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis

Published:2021-10-11 Issue:1 Volume:27 Page:165-174
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Isobe Teruki,Naiki Taku^ORCID,Sugiyama Yosuke,Naiki-Ito Aya,Nagai Takashi,Etani Toshiki,Nozaki Satoshi,Iida Keitaro,Noda Yusuke,Shimizu Nobuhiko,Tomiyama Nami,Banno Rika,Kubota Hiroki,Hamamoto Shuzo,Ando Ryosuke,Kawai Noriyasu,Yasui Takahiro

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-02046-z.pdf

Reference31 articles.

1. Takashi K (2016) Understanding the biology of urothelial cancer metastasis. Asian J Urol 3(4):211–222

2. Slongo J, Jain RH, Spiess PE (2019) Important caveats of KEYNOTE-045: relevance of these findings in the current and future therapeutic paradigm. Ann Transl Med Mar 7(Suppl):S23

3. Lee JH, Kang SG, Kim ST et al (2014) Modified MVAC as a second-line treatment for patients with metastatic urothelial carcinoma after failure of gemcitabine and cisplatin treatment. Cancer Res Treat 46(2):172–177

4. De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191–199

5. Yuasa T, Urakami S, Yonese J (2018) Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol 23(4):599–607

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geriatric nutritional risk index and controller nutritional status score before metastatic first-line chemotherapy predict survival in patients over 70 years of age with metastatic bladder cancer;Frontiers in Medicine;2024-05-10

2. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study;Cancers;2024-04-28

3. Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis;British Journal of Cancer;2024-01-17

4. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

5. The Geriatric Nutritional Risk Index Predicts Prognosis in Japanese Patients with LATITUDE High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Center Study;Cancers;2023-11-08